11 top vaccines for 2020 Pfizer has 4 seats! Johnson and Johnson, Mercer East, GlaxoSmithKline.

Vaccines are suddenly big news as the new crown pandemic spreads around the world.
Although the focus is on the development of COVID-19 vaccine candidates at a record rate, the latest news on the 13th, there are currently about 40 new crown vaccines in clinical trials, of which 10 have entered Phase III clinical trials, the vaccine is expected to be released as early as December this year to early next year, it is expected that the next 6 to 12 months will be more than clinical trial results.
the new crown vaccine, biopharmaceutical companies have not given up promising vaccine programs for other epidemics.
Recently, fiercePharma's website summarized the most notable late-stage vaccine projects of 2020 in addition to the COVID-19 vaccine (COVID-19 vaccine research and development project can be found: an inventory of the current state of vaccine research and development around the world), and Avalere, a healthcare consulting firm, conducted a preliminary study.
four of the 11 vaccines selected are from Pfizer, which will result in significant revenue growth for the Pfizer vaccine product line over the next 10 years.
biotech company, Novavax, is second only to Pfizer, with two candidates selected as the dark horse in the vaccine industry.
addition, Mercadon, GlaxoSmithKline, Johnson and Johnson, Takeda have highlights worthy of attention, it remains to be seen.
Pfizer Prevnar 20 against disease: 20 pneumococcal virus for years, Pfizer has relied on its best-selling pneumococcal infection vaccine Prevnar 13 (Pyre 13).
But competition in the market does not allow Pfizer to meet the status quo, SVB Leerink analysts wrote in a September report that Pfizer is planning to approve its 20-price pneumococcal-binding vaccine, Prevnar 20, in mid-2021 and submit an application to the FDA later this year.
could grab a $1 billion market with Mercedon, which also plans to get FDA approval for its 15-price pneumococcal vaccine next year.
analysts predict that the Prevnar 20 is likely to absorb most of the sales of the older version over time.
Prevnar 13 generated $5.85 billion in global revenue in 2019, making it the world's best-selling vaccine.
new version prevents 13 serotype streptococcus (1,3,4,5,6A, 6B, 7F, 9V, 14, 14, 13) including Prevnar 13 18C, 19A, 19F, 23F) and 7 other seroslots (8, 10A, 11A, 12F, 15BC, 22F and 33F).
Prevnar 13's U.S. patent expires in 2026, but Pfizer says the Prevnar 20 is more effective than Prevnar 13 and rival Mercedon's 15 pneumococcal vaccines.
March, Pfizer published the results of Prevnar 20's Phase 3 clinical study, which showed that 19 out of 20 serotypes over the age of 60 met immunogenic targets, including all serotypes covered by Prevnar 13.
the company expects to release full data in October.
in adults aged 18-59, the vaccine met the standard in all 20 serotonies.
, Pfizer provided Phase 2 research data showing that three injections of Prevnar 20 were similar in safety to Prevnar 13 and induced an immune response to all 20 serotonies in infants.
but the company's key Phase 3 trials in children, which began in May, are likely to last until 2022.
Pfizer's vaccine product line, the Prevnar 20 is just one of the most promising candidates.
SVB Leerink said Pfizer has three more late-stage vaccine candidates that will add more sales potential beyond the Prevnar brand and will achieve "significant revenue growth" by 2028.
three candidates are the pyrethroococcal co-vaccine, the Thyrobacter pyrethroide vaccine and a maternal vaccine against respiratory syncytial virus (RSV).
Pfizer PF-06928316 targets disease: Respiratory syncytial virus (RSV) Although the RSV vaccine is not available in the short term, Pfizer RSVpreF may be the leading candidate in the field, and the vaccine is conducting a post-maternal study to determine whether it is possible to protect babies from RSV by vaccinating their mothers during pregnancy.
but listing approvals may have to wait until 2024.
Pfizer began the phase 3 study in June, conducting a placebo-controlled trial in about 6,900 pregnant women ages 18-49 in the U.S. and several other countries, and tracking respiratory infection rates and potential side effects in newborns after vaccination.
, the study is not expected to conclude until August 2023.
2018, the RSV vaccine has been approved by the FDA as fast-track.
the U.S. Centers for Disease Control, about 57,000 children 5 years of age and younger are hospitalized each year for RSV infections.
about 120,000 children worldwide die each year from RSV.
Pfizer executives had previously said they hoped the vaccine would protect babies for months, or in the first RSV infection.
Pfizer estimates that the RSV vaccine, as well as C.difficile and meningitis programs, could together lead to a $6 billion sales spike.
in RSV vaccine development, Novavax has released the results of two failed Phase 3 trials, immunization in the elderly and in mothers.
but the company has not given up its vaccine candidate.
addition, GlaxoSmithKline, Johnson and Johnson and Bavarian Nordic RSV vaccine candidates are in Phase 2.
Sanofi and AstraZeneta's monoclonal antibody nirsevimab has entered Phase 3 research aimed at preventing lower respiratory tract infections caused by RSV.
analysts at SVB Leerink said there were questions about whether Pfizer's vaccine would have an advantage over nirsevimab.
the antibody will be available in 2023, a year ahead of the Pfizer vaccine.
, the multi-billion dollar market is taking shape.
expects the entire field of vaccine sales to double by 2028.
pneumococcal vaccine will remain the largest market during this time, and the RSV vaccine is likely to jump to second place.
analysts at GlobalData in London believe sales of RSV products will reach $5bn by 2028.
the first class of RSV vaccines and antiviral drugs "will coexist", but their overall impact will depend on cost-effectiveness and absorption in key markets.
Pfizer PF-06886992 for disease: Meningococcal infection in the next generation of meningitis vaccine competition, Pfizer and GlaxoSmithKline candidates have become competitors.
both companies have recently started Phase 3 clinical trials and both plan to achieve results in 2022.
PF-06886992 is a vaccine that Pfizer has approved for meningococcal vaccine Men ACWY in combination with Nimenrix and Men B vaccine Trumenba, and began Phase 3 clinical trials in June to see if the vaccine candidate matches the effectiveness of existing vaccines to prevent meningococcal.
the trial recruited about 2,400 participants, including those who had and had not been vaccinated against meningitis in the past.
SVB Leerink said Pfizer plans to file an approval application in the first half of 2023 and is likely to do so in 2024.
2019, Pfizer's four-priced meningococcal vaccine Nimenrix generated $230 million in global revenue, up 65 percent from the previous year.
same time, Trumenba, the meningococcal B vaccine, sold $135 million, up 16 percent from a year earlier.
, GlaxoSmithKline's meningitis vaccine earns about 1 billion pounds ($1.3 billion) a year.
Pfizer executives argue that the current differences between meningitis vaccines have led to poor compliance and low sales of existing vaccines, as well as a lack of understanding among consumers and doctors.
vaccine will address this problem and thus increase compliance among older, younger and younger people.
rare invasive meningococcal infection can cause death within 24 hours and can also lead to lifelong injuries such as limb loss or hearing loss.
Pfizer's candidate vaccines target almost all case types, including five meningococcal types (A, B, C, W and Y), and no 5-in-1 vaccine has yet been approved on the market.
Pfizer PF-06425090 for disease: C.difficile PF-06425090 is designed to prevent Clostridium difficile infections that often occur in hospitals or long-term care facilities by triggering antibody reactions to two major virulogens from the bacteria.
the vaccine candidate enters Phase 3 clinical studies in 2017 and final results are expected later this year.
if approved, the vaccine would be the first to be immunized against Thyrobacter difficile infection.
Pfizer expects the vaccine to go on sale in 2021, creating a $300 million peak in sales.
but analysts at Barclays believe the outlook goes beyond that.
the vaccine candidate has the potential to drive an inflection point in the growth of Pfizer's vaccine business, resulting in a lasting revenue contribution to the company.
C.diff, which infects about 500,000 people and kills 25,000 people in the United States each year, is now open.
had a late-stage candidate before Sanofi, but after a major trial failed, Sanofi abandoned the project.
addition to Pfizer, only Valneva's candidate vaccine VLA84 for C.diff has completed Phase 2 research.
addition, this market opportunity is quite large.
millions of patients are hospitalized or given antibiotics each year, and about 15 million have severe complications.
Pfizer needs strong data to build a market for recommendations from vaccine experts at the Centers for Disease Control and Prevention.
analysts say the vaccine has a high-risk/high-return opportunity and is expected to generate $2 billion in revenue by 2030.
Mercedon V114 for disease: 15-price pneumococcal virus Although the Pfizer Prevnar 13 vaccine in sales and follow-up to a new generation of products in the lead, but Mercedon also with its own 15-price pneumococcal virus vaccine to join the market competition.
with the release of key data from Phase 3 clinical studies and the FDA's application, Mercedon is catching up with its competitors.
said in September that it planned to apply for approval for its 15-price vaccine V114 by the end of the year.
its Phase 3 study, the vaccine matched the effectiveness of the Prevnar 13 vaccine and surpassed even the old vaccine in three key serotonies.
includes anti-serotypes 22F and 33F, V114 is superior to Prevnar.
, 13 percent of invasive pneumococcal disease patients in U.S. adults 65 years and older are caused by these two serotypes, and 7 to 12 percent of patients in Europe are caused by the virus, Mercer said.
V114 also beat Prevnar 13 in preventing serotype 3.
serotype 3 streptococcus pneumoniae is the main cause of invasive pneumococcal disease worldwide.
researchers track immunogenicity by looking at phagocytostic activity, a vaccine-induced functional antibody.
September, Mercedon published the main results of only two Phase 3 clinical studies.
study showed that subjects who were vaccinated against three different batches of V114 had the same immune response for all 15 serotypes.
16 more late-stage studies are under way to provide more data support for vaccine launches.
with Mercedon planning to submit a vaccine listing application, it will compete directly with Pfizer's Prevnar 20, a older generation of Prevnar 13 that has generated market value of $5.8 billion in annual sales.
industry analysts say doctors are looking at which companies will first introduce the next generation of adult vaccines and first vaccinate children.
, doctors will be concerned about whether approval will change the Centers for Disease Control and Prevention's vaccine recommendations and the potential pricing of products.
analysts at SVB Leerink predict that Pfizer's Prevnar 20 will eventually win a majority of adults.
and Mercedon will have an advantage over the baby population, which is ahead of Pfizer in the data.
as early as January 2019, Mercedon V114 was recognized by the FDA as a breakthrough therapy for the prevention of pneumococcal virus in groups between 6 weeks and 18 years of age.
Pfizer only released data on its Infant Phase 3 study in September of that year, showing that the efficacy was comparable to that of Prevnar 13.
Novavax ResVax for disease: RSVNovavax's recent focus has been on the COVID-19 vaccine, but it has been pushing for RSV and influenza vaccine programs for years.
at RSV, it's not an easy route.
the company's stock failed in 2016 in its Phase 3 study of ResVax, an RSV candidate vaccine, in older people, and then failed again in a study that tested babies protected by maternal immunity, and even so, drug regulators recommended that it conduct another Phase 3 trial.
the vaccine was 44% effective for RSV and LRTI inpatients and 48% effective for severe hypoxemia.
, the company is discussing opportunities to bring ResVax to global markets with a number of potential business partners.
RSV is very common, pass.